Loading…
AOTI's 2024 results: 32.9% revenue growth & 368.7% EBITDA surge, driven by Medicaid expansion, VA contract renewal & FDA-cleared wound care innovation.
This article covers information on AOTI, Inc..
LON:AOTIWhen a medical tech firm grows revenues by nearly a third while turbocharging EBITDA by 368%, you’ll want to put the kettle on and pay attention. AOTI’s 2024 results aren’t just good – they’re the kind of numbers that make growth investors weak at the knees. Let’s dissect this wound care pioneer’s performance like one of their clinical trials.
This isn’t just growth – it’s profitable growth. The Medicaid segment’s 84% revenue jump suggests AOTI is cracking the code on America’s $14B+ chronic wound market.
With an 88% reduction in hospitalisations and 71% fewer amputations in studies, TWO2® therapy isn’t playing nice with competitors. Their NHS cost-saving study (post-period) is a regulatory Trojan horse.
FDA clearance for home-use NPWT systems? That’s like giving diabetics a wound care Swiss Army knife. 85-strong sales team suggests they’re serious about scaling adoption.
The customisable budget impact model isn’t just spreadsheet wizardry – it’s a $72M/year savings pitch to Virginia Medicaid. When you can show payers the money, doors swing open.
VA revenue dipped to 59% of mix (from 72%) as Medicaid and workers’ comp channels accelerated. This isn’t just diversification – it’s margin alchemy:
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
68 viewsLikes
No ratings yet
“We’re not just selling devices – we’re selling durable healing.” – Dr. Mike Griffiths, CEO
Trade receivables ballooned to $13.4M (from $5.2M) as non-VA business grew. While concerning at first glance, the $5M insurer dispute resolution post-period shows proactive management. Still – one to watch like a healing ulcer.
The NHS Supply Chain inclusion (effective Sept 2025) could open England’s 7.6M+ diabetics to TWO2® therapy. That’s not just growth – it’s geopolitical healthcare arbitrage.
AOTI sits at the intersection of three megatrends:
With gross margins already at 88% and operational leverage kicking in, this could be the rare medtech that scales like SaaS. The 2024 IPO wasn’t just fundraising – it was a coming-of-age party.
AOTI’s 2024 proves chronic wounds can be a growth market. Between Medicaid expansion, NHS inroads, and that tantalising CMS decision, 2025 could see this oxygen therapy play breathe even deeper. Just remember – in healthcare, reimbursement moves at the speed of bureaucracy. Pack patience with your optimism.
Disclosure: This analysis is for educational purposes only. Always consult a financial advisor before making investment decisions. Wound care outcomes may vary – but these financials? They’re clinical-grade impressive.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.